Brokerages Expect Arcturus Therapeutics Ltd (NASDAQ:ARCT) to Announce -$0.58 EPS

Brokerages forecast that Arcturus Therapeutics Ltd (NASDAQ:ARCT) will post ($0.58) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Arcturus Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.63) and the highest estimate coming in at ($0.52). Arcturus Therapeutics reported earnings of ($0.50) per share during the same quarter last year, which would suggest a negative year over year growth rate of 16%. The business is expected to announce its next quarterly earnings results on Monday, October 7th.

On average, analysts expect that Arcturus Therapeutics will report full-year earnings of ($2.32) per share for the current fiscal year, with EPS estimates ranging from ($2.54) to ($2.02). For the next year, analysts expect that the business will report earnings of ($2.01) per share, with EPS estimates ranging from ($2.41) to ($1.43). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Arcturus Therapeutics.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.15). The firm had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $3.47 million. Arcturus Therapeutics had a negative return on equity of 132.46% and a negative net margin of 124.59%.

Several brokerages recently weighed in on ARCT. Chardan Capital set a $18.00 price target on Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 20th. HC Wainwright set a $2.00 price target on POET Technologies and gave the stock a “buy” rating in a research note on Friday, April 5th. ValuEngine raised United Overseas Bank from a “sell” rating to a “hold” rating in a research note on Monday, June 17th. Finally, Zacks Investment Research raised FirstService from a “strong sell” rating to a “hold” rating and set a $110.00 price target on the stock in a research note on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $13.83.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARCT. Creative Planning bought a new position in Arcturus Therapeutics in the first quarter valued at about $416,000. Nikko Asset Management Americas Inc. bought a new position in Arcturus Therapeutics in the first quarter valued at about $438,000. Finally, ARK Investment Management LLC lifted its holdings in Arcturus Therapeutics by 13.7% in the first quarter. ARK Investment Management LLC now owns 927,144 shares of the biotechnology company’s stock valued at $6,332,000 after acquiring an additional 111,968 shares during the period. 11.15% of the stock is currently owned by hedge funds and other institutional investors.

ARCT stock traded down $0.60 during midday trading on Thursday, hitting $8.99. The stock had a trading volume of 48,800 shares, compared to its average volume of 51,070. The stock has a market cap of $121.09 million, a price-to-earnings ratio of -4.16 and a beta of 2.30. The stock’s 50-day moving average price is $7.86. Arcturus Therapeutics has a 52-week low of $4.11 and a 52-week high of $10.29. The company has a current ratio of 2.51, a quick ratio of 2.51 and a debt-to-equity ratio of 2.43.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.

Recommended Story: What are the advantages to having securities held in street name?

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.